GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS
Revenue$7.6 billion+10% YoY
EPS$1.56
Outlookraisedguidance
Earnings release · GILD
GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS
Gilead Sciences, Inc. · Filed · SEC Form 8-K, Item 2.02
Revenue
$8.2 billion
+16% vs a year ago
EPS
$1.94
not detected
Guidance
raisedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete.
Please read the original before relying on any figure. Not investment advice.
Why it matters
Revenue rose 16% year on year to $8.2 billion, and EPS was $1.94. Year-on-year revenue change of +16% improved on the +10% in the company's previous release (filed August 2026). Management raised its outlook, and guidance changes often matter more to the market than the quarter just reported because they reflect expectations for the periods ahead.
Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.
What the company states
Revenue
$8.2 billion +16% vs a year ago
…Product Sales Excluding Veklury Increased 16% Year-Over-Year to $8.2 Billion.…
EPS
$1.94
…Diluted earnings per share (“EPS”) was $1.94 in the third quarter 2026 compared to $2.43 in the same period in 2025.…
Guidance
Guidance raised
…“Our performance enabled us to raise our full year base business revenue guidance again this quarter, bringing the total increase to $1.6 billion since the start of 2026.…
Compared with the previous report
Aug 4, 2026 →| Previous (Aug 4) | This release | Change | |
|---|---|---|---|
| Revenue growth (YoY) | +10% | +16% | +6.0 pts |
| EPS growth (YoY) | — | — | — |
| Guidance | raised | raised | — |
“pts” = percentage points of year-over-year growth, current release minus previous release.
Trend: last 2 reports
All releases →Other releases from Gilead Sciences, Inc.
All →
Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.